Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Giri, Pratyush
Patil, Sushrut
Ratnasingam, Sumita
Prince, H. Miles
Milliken, Samuel
Meijide, Javier Briones
Coyle, Luke
Van der Poel, Marjolein
Mulroney, Carolyn M.
Farooqui, Mohammed Z. H.
Wong, Hansen
Desai, Rajendra
Zugmaier, Gerhard
Mergen, Noemi
Cannell, Paul
机构：
[1] Royal Adelaide Hosp, Adelaide, SA, Australia
[2] Alfred Hosp & Monash Univ, Melbourne, Vic, Australia
[3] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia
[4] Epworth Healthcare, East Melbourne, Australia
[5] Sir Peter MacCallum Canc Inst, East Melbourne, Australia
[6] St Vincents Hosp, Darlinghurst, NSW, Australia
[7] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
[8] Royal Northshore Hosp, St Leonards, NSW, Australia
[9] Maastricht Univ, GROW Sch Oncol & Dev Biol, Div Hematol, Dept Internal Med,Med Ctr, Maastricht, Netherlands
[10] Univ Calif San Diego, La Jolla, CA USA
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] Amgen Clin Pharmacol Modeling & Simulat, South San Francisco, CA USA
[13] IQVIA Inc, Biostat Sci, Mumbai, India
[14] Amgen Res Munich GmbH, Munich, Germany
[15] Royal Perth Hosp, Dept Med, Perth, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19584
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [42] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Yung, Mallory
    Schnell, Frederick
    Vukcevic, Mirko
    Kurukulasuriya, Nuwan C.
    BLOOD, 2021, 138 : 1928 - +
  • [43] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    Assouline, Sarit
    Hertzberg, Mark
    Kim, Tae Min
    Kim, Won-Seog
    McMillan, Andrew
    Ozcan, Muhit
    Hirata, Jamie M.
    Penuel, Elicia
    Cheng, Ji
    Ku, Grace
    Flowers, Christopher R.
    BLOOD, 2018, 132
  • [44] A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
    Westin, Jason R.
    Maris, Michael B.
    Al-Katib, Ayad M.
    Lakhani, Nehal J.
    Patel, Prapti Arvind
    Harb, Wael A.
    McCaul, Kelly
    Patel-Donnelly, Dipti
    Messmann, Richard Adam
    Klencke, Barbara J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
    Abdulhaq, Haifaa
    Hwang, Andrew
    Mahmood, Omar
    ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
  • [46] Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
    Palomba, Maria Lia
    Cartron, Guillaume
    Popplewell, Leslie
    Ribrag, Vincent
    Westin, Jason
    Huw, Ling-Yuh
    Agarwal, Shefali
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 504 - 512
  • [47] Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study
    Wang, Yucai
    Laplant, Betsy
    King, Rebecca L.
    Micallef, Ivana N.
    Ansell, Stephen M.
    Tun, Han W.
    Iqbal, Madiha
    Thanarajasingam, Gita
    Rosenthal, Allison C.
    Inwards, David J.
    Johnston, Patrick B.
    Porrata, Luis F.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    BLOOD, 2021, 138
  • [48] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
    Hutchings, M.
    Dickinson, M.
    Carlo-Stella, C.
    Morschhauser, F.
    Bachy, E.
    Corradini, P.
    Iacoboni, G.
    Khan, C.
    Wrobel, T.
    Offner, F.
    Trneny, M.
    Wu, S. -J.
    Cartron, G.
    Hertzberg, M.
    Sureda, A.
    Perez-Callejo, D.
    Lundberg, L.
    Relf, J.
    Clark, E.
    Humphrey, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
  • [49] Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
    Wilson, Wyndham H.
    Phillips, Tycel
    Popplewell, Leslie
    de Vos, Sven
    Chhabra, Saurabh
    Kimball, Amy S.
    Beaupre, Darrin
    Huang, Da Wei
    Wright, George
    Kwei, Kevin
    Ping, Jerry
    Neuenburg, Jutta K.
    Staudt, Louis M.
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2094 - 2106
  • [50] PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: KEYNOTE-013
    Zinzani, P. L.
    Ribrag, V.
    Moskowitz, C. H.
    Michot, J. M.
    Kuruvilla, J.
    Balakumaran, A.
    Thompson, S.
    Marinello, P.
    Chlosta, S.
    Shipp, M. A.
    Armand, P.
    HAEMATOLOGICA, 2016, 101 : 320 - 321
12345